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ABSTRACT 
Stroma, or activated connective tissue, is a key component in both pancreatitis and pancreatic 
tumors. Acute pancreatitis (AP) is an inflammation of the pancreas which ranges from mild and 
local to systemic with severe complications and high mortality. In paper I, we sought out to 
identify new potential biomarkers of AP, by comparing gene expression in mice with caerulein 
induced AP and control mice injected with sodium chloride. Regulator of calcineurin 1 (Rcan1) 
arose as the most promising candidate for an early marker of AP and was found to be regulated 
by oxidative stress, as it was upregulated by caerulein and H2O2 and this upregulation was 
inhibited by the antioxidant N-acetylcystein. Rcan1 protein was also found upregulated in the 
blood of mice early on after AP induction, and in patients with AP, suggesting the potential use 
of RCAN1 as a marker of AP in e.g. post-ERCP-pancreatitis.   
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and 
has a dismal prognosis, in part due to resistance to available treatments. A desmoplastic stroma 
has become one of the hallmarks of PDAC and is currently receiving more and more attention 
from researchers. Overexpression of High mobility group A2 (HMGA2) protein has been 
associated with many cancers as well as with epithelial mesenchymal transition (EMT) and 
cancer stem cell properties. In paper II HMGA2 was shown to be correlated with lower overall 
survival in a cohort of 253 PDAC patients, acting as an independent prognostic marker. Tumor 
cell HMGA2-positivity was also significantly correlated with the abundance of PDGFRB+ 
stroma. Co-injections of Panc1 cells and pancreatic stellate cells (PSCs) in vivo increased tumor 
growth and also HMGA2 and PGDFRB expression. In vitro, HMGA2 expression was increased 
in Panc1 cells grown in 3D spheroids, both by co-culture with PSCs or TGFB1 stimulation. 
In paper III, the 3D co-culture spheroid models of either Panc1 or HPAFII PDAC cells with 
human PSCs, were extensively characterized by immunohistochemistry (IHC) and real time 
PCR. CK19 staining was utilized to identify the tumor cells by IHC within co-cultures. A novel 
method of detecting cell type specific mRNA expression within the co-cultures without the 
need for physical separation of the cells was also developed, where cells of different species 
(human and mouse) were co-cultured and analyzed by real time PCR using species specific 
primers. Co-culturing of PDAC cells and PSCs was shown to activate the stellate cells and 
increase tumor cell proliferation.   
As presented in the additional preliminary data, PDGFB did not induce TGFB1 expression 
by the PSCs as a possible source for the HMGA2 upregulation in cancer cells. HMGA2 protein 
expression in the 3D co-culture spheroid model was inconsistent and displayed some HMGA2+ 
PSCs in addition to the positive tumor cells. HMGA2 was found to be differentially expressed 
also in 3 clinical PDAC samples and one duodenal cancer, where HMGA2-positivity was found 
in both stroma and tumor cells, close to each other as well as separated.      
In conclusion, this thesis work identified RCAN1 as a novel marker for AP and HMGA2 as a 
prognostic marker of PDAC. A novel 3D co-culture spheroid model of PDAC as well as a novel 
method of identifying cell type specific gene expression in 3D cultures without the need for 
physical separation, were developed. In addition, a complex relationship between HMGA2 
expression in tumor and stroma cells was revealed, although the mechanism is not yet clarified.  
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1. INTRODUCTION 
 
Activated connective tissue, or stroma, is a key component in pancreatitis, and pancreatic 
tumors are typically surrounded by an intense fibrotic scar tissue. Acute pancreatitis (AP) is a 
reversible inflammatory process of the pancreas, which may present with severe complications 
and high mortality 1, 2. AP can also develop into a chronic state, i.e. chronic pancreatitis (CP), 
in which case normal pancreas structure and function is irreversibly altered. CP is the most 
common disease of the pancreas, characterized by progressive inflammation and fibrosis 3. To 
date, no curative treatment exists. Notably, patients with CP bear an increased risk for 
developing pancreatic ductal adenocarcinoma (PDAC). Although PDAC has become the 
subject to increasing research efforts over the past decades, poor response to therapy resulting 
in a dismal prognosis has become the hallmark of this disease. PDAC mortality rate has 
remained high and pancreatic cancer still is the fourth leading cause of cancer related death in 
the world. It is expected to shortly climb to number two on the list, unless a remarkable break-
through is soon attained 4. At least in part, this is due to an almost complete resistance against 
both conventional and targeted chemotherapy. With the present standard of care, conventional 
chemotherapy results in a median life expectancy around 6 months 5. As a result, pancreatic 
cancer cannot be survived as compared with colorectal or breast cancer 6, 7.  
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2. BACKGROUND 
 
2.1 The pancreas 
The pancreas is a glandular organ in the digestive system, located in the abdominal cavity 
posterior to the stomach. Anatomically the pancreas can be divided into the head (in close 
proximity to the duodenum), the body (lying behind the stomach) and the tail (ending adjacent 
to the spleen). The pancreatic duct (Ductus pancreaticus) stretches from the tail all the way 
through-out the organ to the head, where it merges with the common bile duct, passes through 
the papilla of Vater and terminates in the duodenum. The pancreas is made up of two major 
tissue compartments, the endocrine and the exocrine pancreas 8. All cell types of the pancreas, 
endocrine, exocrine and ductal, are of endodermal origin 9. The exocrine and endocrine 
pancreas arise from a common progenitor cell population expressing Pdx1, Ptf1a, and Sox9. In 
the presence of other factors, like Ngn3, Pax4, NeuroD, and Hnf6, these cells contribute to the 
proliferation and differentiation of the endocrine pancreas. In the absence of pro-endocrine 
factors and transcription factors like Ptf1a and Mist1, the exocrine pancreas is developed 8.  
The endocrine part of the pancreas constitutes about 2% of the organ mass. It is composed by 
islands of Langerhans, small islet-like structures spread throughout the pancreas. Three major 
cell types makes up the islets; the alpha, the beta, and the delta cells. All cell types secrete 
hormones, important to metabolic regulation, directly to the blood stream (portal vein). The 
alpha cells produce and secrete glucagon, the beta cells insulin and amylin (Islet amyloid 
polypeptide, IAPP) and the delta cells somatostatin 8. Deficiency of the endocrine part of the 
pancreas is involved in diabetes mellitus and pancreatic neuroendocrine tumors originate from 
the endocrine cells 8.  
Exocrine pancreas produces, secretes and transports several enzymes essential for the digestive 
process to the intestines, and makes up about 90% of the organ mass. The remaining mass of 
the organ, in addition to the endocrine and exocrine parts, are made up of blood vessels, 
lymphatics, nerves and fibrous connective tissue stroma 8. One type of cell of great importance 
for the reactive stroma in pancreatic diseases, which will be described in more detail later on, 
is the pancreatic stellate cell (PSC) 10. The exocrine pancreatic secretion is tightly regulated by 
the neuroendocrine system. The endocrine pancreas is closely integrated anatomically and 
physiologically with the exocrine pancreas and regulates its function. Endocrine and exocrine 
pancreas are richly innervated with central and autonomic nerves, and intra-pancreatic 
postganglionic neurons are activated by efferents arising from the duodenal mucosa. When 
activated, these nerves release acetylcholine, which binds on muscarinic receptors on the acinar 
cells and stimulates secretion. Cholecystokinin (CCK), secreted by brain neurons and small 
intestinal cells, is also a very important mediator of pancreatic exocrine secretion 8.    
The exocrine pancreas is made up of acinar, centro-acinar and ductal cells. The gland is divided 
into lobules containing numerous acini, each made up of a single layer of pyramidal acinar cells 
arranged concentrically around a lumen. The acinar cells are polarized in a basolateral and 
apical axis, and are the cells which are producing the digestive enzymes. The broader base of 
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the pyramidal cells is basophilic and contains the nucleus. The narrow apices of the pyramidal 
cells are facing the lumen and contain eosinophilic zymogen granules filled with precursors of 
pancreatic digestive enzymes, such as lipases (fat digestion), alpha-amylases (carbohydrate 
digestion) and trypsin (protein digestion). As the name denotes, centro-acinar cells are located 
centrally within the acinus, where they form an interface between the acinus and the intercalated 
duct. The intercalated duct continues into intra-lobular ducts made up by the ductular cells. The 
centro-acinar cells and the duct cells secrete bicarbonate and water, resulting in acinar 
secretions being flushed into the pancreatic ducts. The intra-lobular ducts fuse to form the 
interlobular ducts that then open into the pancreato-hepatic (biliary) duct (and to a lesser extent 
directly into the duodenal lumen). Each pancreatic acinus is surrounded by a thin basal lamina, 
scarce stroma and pancreatic stellate cells (similar to the hepatic stellate/Ito cells) 11. The 
quiescent pancreatic stellate cells stain positive for GFAP, nestin, desmin and vimentin. Once 
activated, they express α-smooth muscle actin. The pancreatic stellate cells play important roles 
in the pathogenesis of both chronic pancreatitis and pancreatic cancer 8.    
 
 
 
Figure 1. Anatomy of the pancreas. Republished with permission, from12. a) Gross anatomy 
of the pancreas displaying the pancreatic duct, the common bile duct and the gall bladder, as 
well as the duodenum. b) The exocrine pancreas with the pancreatic duct and the acini. c) A 
single acinus. d) The endocrine pancreas; a pancreatic islet embedded in exocrine tissue.   
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2.2. Acute pancreatitis 
Acute pancreatitis (AP) is an inflammation of the pancreas, which ranges from a mild localized 
disease to a severe systemic inflammatory disease with high mortality. Mild AP is characterized 
by inflammation, edema and damage of the pancreatic parenchyma. Severe AP can induce 
multi-organ failure and extensive pancreatic necrosis, leading to sepsis 13, 14. The two most 
common causes of AP are prolonged excessive alcohol abuse and bile acid reflux due to 
gallstone obstruction 15, 16.  
Under physiological conditions the exocrine pancreas stores inactive precursors of digestive 
enzymes in zymogen granules. The zymogen granules are released from pancreatic acinar cells 
into the pancreatic duct, upon endocrine and neuronal stimuli and the precursors are flushed out 
into the duodenum where they after activation participate in digestion 13. In AP however, the 
general theory is that digestive enzymes are prematurely activated, leading to auto-digestion of 
acinar cells and subsequent inflammation 15, 17. Active digestive enzymes co-localize with 
lysosomal enzymes and form large intracellular vacuoles, inducing the production of pro-
inflammatory cytokines by stimulation of macrophages and acinar cells. 13. Cytokines are 
important players in driving the inflammatory response and hence in the pathogenesis of the 
disease. Tumor necrosis factor alpha (TNF-α) 18, 19 as well as interleukins (IL) such as IL-6 20-
22 are key mediators of inflammation in AP.  
Inflammation leads to production of reactive oxygen species (ROS) and ROS contribute to 
worsening the inflammatory response 23, 24. This complex relationship makes it difficult to 
distinguish if oxidative stress is an initiating event in the pathogenesis of acute pancreatitis, or 
a mediator amplifying the disease. In order to understand the mechanisms of disease 
development, various rodent models of experimental AP have been established. One of the most 
commonly used models is the caerulein induction model. Caerulein is an analogue of CCK, as 
already mentioned an important hormone inducing secretion of digestive enzymes from the 
pancreas. CCK induces ROS production and AP in animals and cells 25, 26.  
ROS 26, 27, as well as the pro-inflammatory transcription factor nuclear factor kappa B (NFκB) 
28, 29, are important mediators of inflammation in AP. Both non-oxidative alcohol metabolites 
and bile acids mediate AP development through prolonged increase of intracellular calcium 
levels in the acinar cells 30. At least in part, the excess of intracellular calcium then acts by 
activating calcium-dependent calcineurin (CN), which dephosphorylates nuclear factor of 
activated T-cells (NFAT). This triggers translocation of NFAT proteins from the cytoplasm to 
the nucleus. There, NFAT then controls the expression of target genes involved in many 
biological functions 31, including zymogen activation. In AP this contributes to damage of the 
acinar cell compartment 32, 33. Bile acids have been shown to activate both NFκB and the pre-
digestive enzyme trypsinogen through induction of CN-NFAT signaling in acinar cells, thus 
inducing acinar cell injury 34. CN-NFAT signaling also upregulates its own endogenous feed-
back inhibitor, Regulator of calcineurin 1 (Rcan1) 35.  
 
  
Bardeesy & DePinho, Nat Rev Cancer, 2002 
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2.3. Regulator of calcineurin 1 
Rcan1 does not only play a role in AP, but also in multiple other diseases, such as 
atherosclerosis and cardiovascular disease 36, 37, Alzheimer´s disease 38, 39, Down syndrome 40, 
41, various cancers 42-46 and others 47. RCAN1 is also known as modulatory calcineurin-
interacting protein 1 (MCP1) and Down syndrome critical region 1 (DCSR1), as it was first 
identified as involved in the pathogenesis of Down syndrome. In addition, a higher expression 
of Rcan1 in brains of young rats compared to adults suggests a role for Rcan1 in the central 
nervous system development 40 and it has also been suggested to play a role in cardio protection 
in the heart 48. 
In neuronal cells, Rcan1 has been shown to be regulated by both CN-NFAT signaling, NFκB 
49 and oxidative stress 50. Knock-down of endogenous Rcan1 in endothelial cells increased 
NFAT activity and stimulated expression of inflammatory genes 51. The specific role of Rcan1 
in the pancreas is not well studied, although Rcan1 overexpression in pancreatic beta-cells was 
shown to cause hypoinsulinemia, beta-cell dysfunction and diabetes 52. Also, CN-NFAT 
signaling induced Rcan1 expression in acinar cells, following damage-induced regeneration 35.  
Over the years, numerous diagnostic and prognostic markers for AP have been evaluated, 
including both single markers as well as more complex multifactorial prognostic systems. In 
spite the many currently available prognosis systems 53, there still is a lack of specific AP 
markers, specifically an early marker that reliably can predict mortality or disease severity. 
 
2.4 Chronic pancreatitis 
Repetitive AP may lead to CP 54, a chronic inflammation of the pancreas and a progressive 
fibrotic destruction of the pancreatic parenchyma 3, 55. CP is mainly characterized by interstitial 
fibrosis and acinar cell atrophy 56. Eventually, the disease leads to a progressive loss of the 
lobular morphology and structure of the pancreas, severe changes in the arrangements and 
composition of the islets, and deformation of the large ducts. This leads to irreversible damage 
resulting in the impairment of both pancreatic endocrine and exocrine function, eventually 
resulting in malnutrition and/or diabetes 55. Increasing evidence indicates that the pancreatic 
stellates cells (PSCs) are major mediators of fibrosis, involved in the production of the fibrotic 
extracellular matrix (ECM) in the interstitial spaces responsible for the morphological changes 
of the pancreas. The pancreatic destruction in CP is associated with the activation of the PSCs 
into myofibroblast-like, α-SMA expressing cells, producing high levels of fibrotic ECM 
proteins, such as collagens I and III and fibronectin 55, 57. Activation of the stellate cells is 
increased by cytokines released by injured acinar cells and infiltrating leucocytes.  
A total loss of secretory tissue, disappearance of immune cells and an intense fibrosis denotes 
the final stages of CP 57. Transforming growth factor beta (TGFB), which is upregulated and 
activated in fibrotic diseases including CP, is the most potent fibrogenic factor known to date 
58.  
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2.5 Pancreatic cancer 
Pancreatic tumors may originate in different cell types of the pancreas and are named thereafter. 
The most common tumors of the pancreas are of ductal, acinar and endocrine cell lineage.  Still, 
neuroendocrine tumors only account for 1-2% of pancreatic tumors. The most common 
pancreatic endocrine tumor is the pancreatic endocrine neoplasms (PENs). Acinar cell 
carcinomas (ACCs) are also very rare, accounting for less than 2% of all pancreatic 
malignancies. In ACCs, pancreatic enzymes such as trypsin and lipase are produced by the 
tumor cells and can be detected by immunohistochemistry 59.  
Pancreatic ductal adenocarcinoma (PDAC) accounts for up 85-90% of pancreatic cancers, 
making it by far the most common of the pancreatic neoplasms. For this reason, the term 
pancreatic cancer is often used synonymous with PDAC. PDACs are solid, poorly defined 
tumors, predominantly occurring in the pancreatic head and measuring about 2.5-3 cm when 
diagnosed. Due to their predominant location to the head, PDACs often cause cholestasis as a 
consequence of narrowing the common bile duct and the pancreatic duct. PDACs also cause 
dense fibrosis of the pancreatic parenchyma. Histologically, the tumors are often well-
differentiated with duct-like structures surrounded by a desmoplastic stroma. The fibrotic 
stroma is characteristic for PDAC and is further discussed in the section on the tumor associated 
stroma (section 2.6). The cancer cells in PDAC commonly express mucins (MUC1, MUC5AC), 
cytokeratins (7, 8, 18, and 19), and p53 protein. The most common genetic mutations in PDAC 
are mutations in the KRAS gene, followed by mutations in TP53, CDKN2A/p16 and SMAD4, 
the latter commonly deleted in PDAC. These mutations are generally regarded as “driver 
mutations”, necessary for the neoplasms to develop 59.  
PDACs are believed to commonly develop through precursor lesions, mainly pancreatic 
intraepithelial neoplasias (PanINs) but also intraductal papillary mucinous neoplasms (IPMNs), 
and mucinous cystic neoplasms (MCNs) 59. The PanINs have been subcategorized into different 
stages, PanIN-1A to PanIN-3. Genetic alterations in the different PanIN stages have been 
identified through tissue microarrays 60. It was revealed that mutations in the PanIN stages occur 
in a specific order during their development, and this order is thought to be necessary for 
malignant transformation analogous to the situation in colorectal cancer 61. Activating KRAS-
mutations and telomere shortening are early events, p16 and MUC1 mutations show up in 
PanIN-2 lesions, whereas mutations in p53 is a later event which generally is detected first in 
PanIN-3 lesions.   
Figure 2. PanIN development in PDAC. Illustration of our current understanding of multistep 
progression of PDACs. Republished with permission from 60.  
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2.6 The tumor associated stroma 
The stroma is defined as the supportive framework of an organ, usually composed of connective 
tissue cells, as distinguished from the parenchyma (tissues or cells performing the special 
function of the organ). The stroma is made up of vascular, epithelial and inflammatory cells 
within an extracellular matrix (ECM) rich environment containing different ECM proteins 
(collagens fibronectin, glycosaminoglycans and proteoglycans). Interestingly, only a small part 
of a tumor is actually made up of cancer cells, and the rest, in extreme cases up to 90%, is made 
up by the tumor stroma (often referred to as the desmoplastic or reactive stroma). Interactions 
between the cancer cells and surrounding cells are gradually getting more in focus, as it is 
becoming increasingly evident that the tumor associated stroma plays a major role in the 
development and progression of cancer. Cancer-associated stromal fibroblasts (CAFs) have 
been shown to promote pancreatic tumor progression 62, 63, and cancer-stroma interactions have 
been shown to be important in promoting tumorigenesis, angiogenesis, therapy resistance as 
well as metastatic spread 64. Tumor-associated macrophages (TAMs, M1 and M2 type), are 
involved in promoting angiogenesis by regulating the angiogenic switch 65, 66, and in promoting 
proliferation and metastasis 66. The production of the tumor associated stroma is promoted by 
growth factors such as fibroblast growth factor (FGF-2), platelet derived growth factor (PDGF), 
and transforming growth factor beta (TGFB1), which are produced by the cancer cells and 
activate fibroblasts to produce more ECM 67.  
 
 
Figure 3. Stromal activation. Quiescent stroma in normal epithelium (a), activated stroma 
in pre-malignant dysplasia (b) and reactive tumor stroma in a carcinoma (c). Image re-
published with  permission from 68.  
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2.7 PDAC stroma  
PDAC is generally characterized by a particularly dense and fibrotic stroma 69. As mentioned, 
the organ residing pancreatic stellate cells (PSCs) are fibroblast-like mesenchymal cells which 
are involved in producing the fibrotic stroma in both pancreatitis 70 and pancreatic cancer 71. 
The role of PSCs in fibrosis and cancer have recently been reviewed 72. The PSCs, similar to 
the hepatic stellate cells responsible for fibrosis in the liver, were first identified and isolated in 
1998 by two independent groups 10, 73. PSCs can be identified by their expression of desmin, 
GFAP and vimentin. Freshly isolated cells have abundant lipid droplets stored in their 
cytoplasm, and a characteristic blue-green fading fluorescence of cytoplasmic vitamin A. 
Initially primary PSCs are negative for α-SMA but after being cultured they stain positive, 
meanwhile the number of cytoplasmic lipid droplets decrease. Culture activated PSCs 73 and 
PSCs activated by pro-inflammatory cytokines 74 produce ECM proteins such as collagen I and 
III, fibronectin and laminin. TGFB1 induces ECM production in cultured PSCs, and PDGF 
increases stellate cell proliferation. TGFB is known to moderate fibroblast phenotype and 
function, inducing myofibroblast transdifferentiation while promoting preservation of the 
ECM. The expression of TGFB is leading to increased stromal stimulation and increased ECM 
production, both in the tumor cells and in the surrounding fibroblasts; in vivo, desmoplasia is 
developing 75. TGFB pro-fibrotic actions are, at least in part, mediated through its downstream 
effector, connective tissue growth factor (CTGF) 58. To facilitate studies of PSC function in 
pancreatic fibrosis, immortalized rodent 76, 77 and human 78, 79 PSC lines have been established.  
The function of the PDAC stroma has been debated and proposed as a double-edged sword. It 
is unclear whether it is a host defence against the cancer, a tumor driven process as to facilitate 
the tumor growth and spread, or possibly context dependent. Up until recently most evidence 
suggested that the role of the stroma was in promoting tumor progression 80. For example, 
pancreatic cancer cells stimulate proliferation and matrix synthesis of PSCs 71 and PSCs 
promote epithelial to mesenchymal transition (EMT) in pancreatic cancer cells 81. Also, as 
mentioned, cancer associated fibroblasts (CAFs) have been shown to promote pancreatic tumor 
progression 62. The standard of care for pancreatic cancer patients, gemcitabine, only modestly 
extends survival for a small subset of patients 82. PDAC response to chemotherapy is generally 
very poor and it was shown that gemcitabine and other drugs have problems to penetrate the 
tumor stroma 83. This could at least in part explain why many drugs showing promising results 
in preclinical in vitro and in vivo models failing to recapitulate the tumor stroma, later on fail 
in the clinic. However, clinical trials targeting the PDAC stroma surprisingly revealed that the 
complete depletion of the stroma is associated with decreased patient survival. Two recent 
papers support this notion. Özdemir et al showed that depletion of CAFs and fibrosis induced 
immunosuppression and accelerated pancreatic cancer growth, reducing survival. This in a 
mouse model with the ability to delete α-SMA+ myofibroblasts in mice with already established 
tumors 84. Rhim et al showed that mice deficient in sonic hedgehog (Shh), had tumors with 
reduced stromal content but that these tumors were more aggressive than tumors with a higher 
content of tumor stroma 85. More recently, a re-education of the stroma rather than a complete 
ablation, has been suggested 86, 87. It is becoming more and more evident that the PDAC stroma 
is much more complex than initially proposed. Öhlund et al. presented two separate but co-
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existing CAF populations, one α-SMA+ CAF population adjacent to the tumor cells and another 
α-SMA-/IL-6+ CAF population, located further away from the tumor cells 88. A recently 
published paper demonstrated an even more complex CAF profile, with four distinct subtypes 
of primary derived CAFs, each with distinct markers and correlations to overall survival as well 
as tumor promoting abilities 89.     
 
2.8 3D cell culture models of PDAC 
Solid tumors in vivo grow in a three-dimensional (3D) conformation with cell-cell interactions 
in all directions, and a heterogeneous exposure to oxygen, nutrients and other chemical and 
physical pressures. This is very different from the monolayer growth of cells in traditional cell 
culture. It is now generally accepted that cell-cell interactions in 3D influence not only cell 
structure and adhesion, but also cell signaling in response to soluble factors, greatly affecting 
cell function 90. 3D culture of tumor cells was introduced already in the early 70’s. Early interest 
was related to the morphology and (ultra-) structure of the tumor cells 91 and later tumor cell-
cell interactions 92. Today, there are various 3D models of human cancer reviewed in e.g. 93, 94. 
3D culture models include multilayered tumor cell cultures, tumor slices, organoids, 3D 
cultures with reconstituted basement membranes and spherical cancer models. Weiswald et al 
recently elegantly reviewed the different variants of spherical tumor models, and proposed a 
rational classification and nomenclature 90. The four suggested classes of spheroid tumor 
models are: the multicellular tumor spheroid (MCTS) model, obtained by culturing cancer cell 
lines under nonadherent conditions; tumorospheres (TS), a model of cancer stem cell growth in 
serum free media supplemented with growth factors; tissue-derived tumorospheres (TTS), 
generated by partial dissociation of cancer tissue and containing only tumor cells; and 
organotypic multicellular spheroids (OMS), obtained by mechanical cutting and dissociation of 
tumor tissue 90. To date, there are various 3D-culture models of pancreatic cancer, counting 
numerous MCTS models 95-97, including our 3D spheroid culture model, characterized by a 
higher ECM expression and significantly increased chemo-resistance compared to cells 
cultured in monolayers 98. There also are various 3D PDAC models of cells grown in/on 
different matrix substrates, e.g. 99-101, tumorosphere models 102-105, as well as mouse and human 
organoids 106-109. Although organoids and OMS derive from and are closer to real tumors than 
other 3D tumor models, there are other qualities which favors the use of simpler models such 
as MCTS. For example, the ease of maintenance and the possibility for high through put drug 
screening and genetic manipulation of the cells 90. Extending MCTS and other matrix 3D 
models to allow for studies of tumor-stromal cross-talk, there also are co-culture models adding 
a stromal compartment. There now are co-culture models including tumor spheroid models of 
cancer cells and fibroblasts in lung cancer and cervical carcinoma 110, melanoma111 , breast 112, 
113, colorectal 114, 115 liver cancer 116 and pancreatic cancer 117, and 3D co-culture models of 
colon cancer 118, 119 and breast cancer cells 113 with macrophages. Recently, also a triple cell co-
culture model of pancreatic cancer was developed, containing tumor cells, fibroblasts and 
endothelial cells 120.  
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2.9 Mouse models of PDAC 
Many genetically engineered mouse models of human pancreatic cancer have been developed, 
and were recently reviewed by Mazur and Siveke 121. Currently, the KrasLSL-G12D/+;Trp53LSL-
R172H/+;Pdx-Cre (KPC) genetically engineered mouse model (GEMM) 122 is the most accurate 
and validated preclinical in vivo model of human pancreatic cancer, successfully recreating the 
dense stroma seen in the human disease which other in vivo models (subcutaneous, orthotopic) 
have failed to develop so far. In mice expressing the KrasLSL-G12D/+ allele 123, PanIN lesions 
occur in pancreatic acinar cells developing into ductal cells through acinar-to-ductal metaplasia. 
These progressive lesions recapitulate all features of human PanIN stages 1, 2 and 3, and local 
invasive cancer develops in 9-12 months. In combination with the Trp53LSL-R172H/+ allele 122, 
latency time is reduced to 3 to 5 months and 60% of the mice develop metastases to the same 
sites as in humans.  
Depending on the question asked simpler injection models may however be the best choice. 
Cells may be injected subcutaneously under the skin or orthotopically into the pancreas. Co-
injection of PDAC cells and PSCs resulted in enhanced tumorigenicity 124, 125 and PSCs were 
shown to be involved in metastasis in vivo 125. 
 
2.10 High mobility group A2  
The HMGA2 protein belongs to the family of non-histone chromosomal high-mobility group 
proteins (reviewed in 126-129). These proteins are known to alter DNA structure and consequently 
regulate DNA-dependent activities, like transcription, replication and repair 128. The AT-hook 
is a structural DNA-binding motif in the HMGA2 protein, which enables binding to the minor 
groove of AT-rich DNA regions 130. It also promotes the recruitment of additional 
transcriptional regulators and makes up part of the so called enhanceosome, by interaction with 
multiple protein complexes on promoter/enhancer sites 130, 131. HMGA2 has been suggested to 
play a role in regulation of cell proliferation and differentiation, due to its high expression in 
the embryo and complete or close to absence in adult human tissue 128, 131, 132. In neoplastic 
cells, HMGA2 expression is often re-induced and its involvement in the regulation of EMT and 
cancer stem cell properties has been demonstrated 133, 134. This goes in line with HMGA2 over-
expression being found associated with metastasis and poor prognosis e.g. in non-small cell 
lung cancer 135, gastric cancer 136, 137, colorectal cancer 138, triple negative breast cancer 139 and 
ovarian cancer 140. In PDAC, HMGA2 expression was found associated with loss of tumoral E-
Cadherin expression 131, lymph node metastases and high tumor grade 141, 142. One study, limited 
to 91 cases of PDAC, also identified an association with poor prognosis in evaluations limited 
to univariate analysis 143. Both epithelial growth factor (EGF) and TGFB have been shown to 
act as inducers of HMGA2 134, 144.  
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2.11 Transforming growth factor beta signaling  
There are three strongly conserved TGFB genes giving rise to three distinct isoforms known as 
B1, B2 and B3, TGFB1 being the one mainly involved in the immune system. When secreted 
in vivo, TGFB is incorporated as a part of an inactive complex in the extra-cellular matrix 
awaiting activation. Once activated, TGFB1 and B3 bind to TBRII with high affinity, whereas 
TGFB2 requires the presence of type III TGFB receptor (TBRIII) to efficiently bind TBRII. 
Ligand-bound TBRII then recruits and activates TBRI through phosphorylation, which in turn 
phosphorylates and activates downstream SMAD proteins. The SMAD proteins are 
transcription factors and SMAD2 and SMAD3 are directly activated by TBRI phosphorylation. 
This causes a conformational change, allowing SMAD2/SMAD3 to form a heterotrimeric 
complex with SMAD4 which then translocates to the nucleus and regulates gene transcription 
145-148. The involvement of the canonical activin receptor-like kinase 5/Smad3 pathway in 
fibrosis, has been demonstrated in a wide range of experimental models 58. SMAD7 is also 
activated by TGFB but acts as the main negative feedback regulator of TGFB signaling 149. 
TGFB downstream signalling can also be mediated through SMAD-independent pathways 147, 
150.  
TGFB is a pluripotent cytokine which is expressed in almost every cell type of the body. Its 
role in fibrosis has been subject to intensive investigation but is not yet fully understood, and 
the exact contribution of the different cellular compartments of the pancreas with respect to 
TGFB as source and effect in the role of fibrosis is not known. TGFB is also involved in cancer, 
through its role in immune function 151, 152 , cell growth, apoptosis, angiogenesis and metastasis, 
first acting as a tumor suppressor and later as a tumor promotor 147, 153-156.  
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3. AIMS 
 
The overall aim of this thesis is to enhance the understanding of the role of the reactive stroma 
in pancreatic diseases, namely pancreatitis and pancreatic ductal adenocarcinoma.  
 
Specific Aims 
 To investigate the role of pancreatitis-related genes and identify potential biomarkers 
of acute pancreatitis.  
 
 To establish, characterize and validate a 3D co-culture spheroid model of pancreatic 
cancer and stellate cells.   
 
 To investigate the role of tumor cell to stromal cell crosstalk in promoting pancreatic 
cancer carcinogenesis, using the established 3D in vitro model. 
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4. PATIENTS, MATERIALS AND METHODS 
 
Here I will briefly discuss patients, materials and methods, with a focus on the key methods 
used for my own contribution to the studies and related experiments. More comprehensive and 
detailed descriptions are available in respective paper. 
 
4.1 Cell culture (Papers I-III + additional data) 
The Panc1, HPAFII, AR42J, AsPC1 and CFPAC-I cell lines were purchased from ATCC. The 
immortalized pancreatic fibroblasts (PSCs/hPSCs) were derived from a patient with chronic 
pancreatitis as described in 78, and the KPCT 86-2 cell line was isolated in-house from a KrasLSL-
G12D/+;Trp53LSL-R172H/+;Pdx-Cre (KPC) mouse 122 mated to the tdTomato allele (B6.Cg-
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) 157. The immortalized mouse pancreatic stellate cell line 
clone 3 (imPSCc3; in text and figures referred to as mPSC) was a kind gift from Dr. Raul 
Urrutia and Dr. Angela Mathison at the Mayo Clinic College of Medicine, Rochester, Minn, 
USA, the Panc1-H2B-mCherry cells from Dr. Maarten Bijlsma at the Academic Medical 
Center, Amsterdam, The Netherlands 77 and the PaCa44 from Günter Klöppel at the Technical 
University of Münich, Germany. Panc1-mock (Panc1-M) and Panc1 overexpressing TGFB1 
(Panc1-T) cell lines were previously established by JML 75. The HPDE cells were a kind gift 
from Patrick Michl (University Hospital Halle, Germany). 
HPAFII and CFPAC-I cells were cultured in RPMI-1640 medium, AR42J cells in F12-K and 
all other cell lines in DMEM/F12. All cell lines were cultured under standard culture conditions 
(5% CO2, at 37°C), supplemented with fetal bovine serum (FBS) (20% for AR42J cells and 
10% for all other cell lines) and penicillin/streptomycin. All cell lines were tested negative for 
mycoplasma (MycoAlertTM PLUS Mycoplasma Detection Kit, LT07-705, Lonza, 
Switzerland) before initial use and regularly thereafter. Primary murine acinar cells were also 
isolated and cultured, as described previously in 158 as well as in paper I.    
For more detailed information on culturing of the cells and specific cell culture experiments, 
see specific article or manuscript. 
 
4.2 3D co-culture spheroid assay (Papers II and III + additional data) 
Tumor cells and PSCs were seeded alone or in co-culture (1:1), at a total concentration of 2500 
cells/well. Cells were seeded in culture media with a final concentration of 0.24% of the 
crowding agent methylcellulose, in non-cell culture treated round bottom 96-well plates 
(Falcon, BD NJ, USA). For spheroid preparations, all cells were seeded in DMEM/F12 media. 
A more thorough description of the 3D co-culturing method is described in 98, as well as in 
papers II and III, along with detailed information on further processing.   
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Shortly, for dissociation (paper II) spheroids were treated with trypsin/EDTA at 37ºC followed 
by trituration, in a series of steps. Trypsin was thereafter inactivated by the addition of FBS-
containing media and cells were further processed for fluorescence activated cell sorting 
(FACS). To prepare spheroids for immunohistochemical analysis (paper III), the 3D cultures 
were fixed in 4% paraformaldehyde, dehydrated in 70% ethanol and then embedded in 
HistoGel, according to a protocol modified from 159, as described in paper III.  
For specific information on antibodies, see the manuscript. For electron microscopy analysis, 
spheroids were fixed in 2.5% glutaraldehyde buffer.   
Mono-cultured Panc1 tumor cells treated with TGFB1 (paper II + additional data) were seeded 
in the same way as other mono- and co-cultures, except in low serum media containing 0.5% 
FBS. The cells were seeded in the presence of 5 ng/ml TGFB1 or equal volume of vehicle 
control and then treated again on day 3 at double concentration, as to compensate for the media 
volume already present in the well.  
 
4.3 Patient samples 
4.3.1 AP patients (paper I) 
Peripheral blood samples were collected from patients at the Royal Liverpool University 
Hospital (Liverpool, UK), as well as healthy controls at the Karolinska University Hospital 
(Stockholm, Sweden). AP patient samples were collected within 24 hours of admission (48 
hours of onset of abdominal pain; NIHR Liverpool Pancreas Biomedical Research Unit Acute 
Pancreatitis Biobank), from patients with mild, moderate and severe AP. 
All sample collections were done in accordance with local ethical guidelines (REC 15/YH/0193 
for Liverpool Hospital, approved by NRES Committee Yorkshire & The Humber - Sheffield; 
EPN Dnr 2014/1155-31/4 and 2016/2090-32 for Karolinska Hospital approved by Regionala 
etikprövningsnämnden i Stockholm). Each volunteer agreed to sample collection and use 
through written consent. 
 
4.3.2 PDAC patients (paper II) 
In this study, four hundred and forty-five patients from the Herley Hospital (n=277) and 
Rigshospitalet (168), both University of Copenhagen, Denmark, were included. They all 
underwent pancreatic resection between 1976 and 2012. Due to an unclear cause of death, 37 
patients were excluded from analyses. Out of the included patients, 253 had PDAC and will be 
the focus of this thesis, whereas 155 had ampullary adenocarcinoma (AAC). The study was 
approved by the local Ethical committee (H-KA-20060181 and VEK ref. KA-200601113) and 
the Danish Data Protection Agency (j.nr. 2006-41-6848).  
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4.4 Mouse models 
4.4.1 Acute pancreatitis experimental mouse model (Paper I) 
The caerulein induction model of acute experimental pancreatitis 160, was utilized in wild type 
C57Bl/6J mice (Scanbur-BK, Sollentuna, Sweden). Caerulein, at 50 µg/kg, was injected 
intraperitoneally (i.p) 9 times hourly. Control mice were injected with the corresponding 
volume of saline. One hour after the last injection, mice were anesthetized and cardiac blood 
and pancreas was collected. Blood samples were used for blood chemistry and ELISA analyses, 
pancreas for mRNA and tissue myeloperoxidase (MPO) activity evaluations.  
A detailed description of the performance of the mouse experiments, collection and processing 
of samples, can be found in the article (ethical permission number: S176-08, ID 707 from 
Stockholms södra djurförsöksetiska nämnd).  
 
4.4.2 KPC mouse model (Paper II) 
The pancreas from KrasLSL-G12D/+; Trp53LSL-R172H;+;Pdx-Cre (KPC) mice 122 were collected at 
different time points. Tissues were fixed in 4% paraformaldehyde at room temperature for 24 
hours and then transferred in 70% ethanol for at least another 24 hours at 4°C before further 
dehydration and paraffin embedding (ethical permission number from Stockholms södra 
djurförsöksetiska nämnd: S31-15).  
 
4.4.3 Co-injection xenograft model (Paper II) 
Panc1 cells alone or together with PSCs at a 1:1 ratio were injected subcutaneously into CB17 
SCID mice (Janvier Labs, Le Genest-Saint-Isle, France, n = 5 per group). Tumor growth was 
monitored twice per week and tumor volumes calculated with the formula (V = length x height 
x width/2). When the tumor volume reached 500 mm3 the mice were euthanized under 
anesthesia, tumors collected and immediately snap frozen in liquid nitrogen (ethical permission 
number 2014.III.02.022, Utrecht University animal ethical board).  
 
All animal experiments were performed in accordance with the local ethical guidelines and with 
the approval of the local ethical committee.  
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4.5 Regulator of calcineurin 1 ELISA (Paper I) 
Whole blood from mice and peripheral blood samples from AP patients and healthy controls 
were collected in EDTA tubes. The samples were processed within 30 minutes of arrival in the 
lab. The resulting plasma was aliquoted and stored at -80°C. Plasma was later diluted in assay 
diluent and assayed in duplicates according to manufacturer´s instructions, in either a mouse 
(CUSABIO, CSB-EL019500MO) or human (EIAab, E13874h) RCAN1 ELISA kit. 
 
The patient samples were also divided into three groups of mild, moderate and severe AP based 
on the clinical diagnosis (n = 19, 13 and 8), according to the revised Atlanta criteria 161, and 
assayed against healthy controls (n = 8). A two-sided Student´s t-test for individual samples 
was used to evaluate the difference between AP patients or mice and respective controls. 
Differences between the three groups of mild, moderate and severe AP patients were evaluated 
by ANOVA. 
 
4.6 Immunohistochemistry (Papers I-III + additional data) 
Murine pancreas head samples (paper I) and human patient samples (paper II) were fixed in 4% 
paraformaldehyde and embedded in paraffin before being sectioned and stained with 
hematoxylin and eosin and antibodies as specified in each paper. Spheroid cultures (paper III), 
were treated the same way except for an intermediate step of HistoGel embedding, between 
fixation and paraffin embedding, as described above.     
More detailed information on analysis can be found in respective paper.  
 
4.7 Transcriptional profiling (Paper I) 
Affymetrix mouse gene 1.0 ST arrays (Affymetrix, Inc., Santa Clara, CA) was used for gene 
expression profiling. Bioconductor packages (www.bioconductor.org) was used for analysis. 
Normalization and gene expression calculations were performed with the Robust Multichip 
Average expression measure, using oligo package 162. Prior to further analysis, a non-specific 
filter was applied in order to include only genes with expression signal > 50 in at least 20% of 
all samples. Differentially expressed genes with an adjusted P value lower than 0.01, were 
identified using Limma package 163.  
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4.8 mRNA isolation and quantitative RT-PCR (Papers I-III + additional data) 
Mouse pancreas samples and cells (papers I-II) and spheroids (papers II-III + additional data) 
were processed for total RNA extraction and reverse transcription. Thereafter, cDNA was 
subjected to real-time PCR. Detailed information on RNA/cDNA preparations, primers, 
housekeeping genes, cycling programs and analyses are found in the respective papers.  
Briefly, delta Ct values for each sample were used for statistical analysis with a Students t-test 
for individual samples, and a p value below 0.05 was considered as statistically significant. 
Relative expression (2^-dCT) values were used to create boxplots (paper I) and mRNA 
expression values normalized to untreated control (papers I-II), corresponding mono-culture 
(paper II), day 3 mono-culture expression (paper III + additional data), or HPDE expression 
(additional data) were used to create staple graphs. Error bars in staple graphs are 95% 
confidence intervals.  
 
4.9 Virtual sorting (Paper III + additional data) 
A method for determination of cell type specific gene expression in 3D spheroid cultures, 
without the need for pre-dissociation and physical separation, was developed and named virtual 
sorting. Spheroid cultures pairing human tumor cells with mouse PSCs and mouse tumor cells 
with human PSCs, were prepared. Cell type specific gene expression was then determined by 
direct real time PCR, using species specific primers specifically developed in regions   
genetically diverse in between the mouse and human homologue genes.  
As a pre-test of species specificity, real time PCR was performed with the developed primers, 
on a test panel including human tumor cells (Panc1), human PSCs (hPSC), mouse tumor cells 
(KPCT 86-2) and mouse PSCs (mPSC). The products from the real time PCR test were also 
run on a 2% agarose gel, in order to ensure species specificity, amplicon size and singularity.  
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5. RESULTS 
 
In this chapter I will summarize the findings from each paper, with focus on the results derived 
from my own contributions to the studies and related results needed to be discussed for a more 
comprehensive picture. More detailed descriptions are available in respective paper. I will also 
present some additional, preliminary data not included in any of the papers.    
 
5.1 Paper I 
5.1.1 Rcan1 and Sesn2 are identified as candidate biomarkers of acute pancreatitis 
Caerulein treatment was shown to induce AP in mice through histological signs of pancreatic 
inflammation, induction of inflammatory cytokines and an increase in serum amylase, the 
clinical standard of AP. Through a gene expression profiling on murine pancreatic tissue, 
mRNA samples from the caerulein treated AP mice and sodium-chloride treated controls (n = 
5-6), 2038 genes were found to be differently expressed in between the groups. The variation 
within each group was very low, indicating high reproducibility of the experimental procedure. 
We screened the literature to find novel candidates for prognostic markers and confirmed the 
upregulation of these candidate genes by real-time PCR in two independent experiments. A 
selection of genes were then further investigated in freshly isolated primary murine acinar cells, 
and Rcan1 and Sesn2 were found to be induced at early time points upon caerulein stimulation.  
 
5.1.2 Rcan1 is regulated by oxidative stress 
Our results from the animal experiments were further verified by inducing AP-like stress in the 
AR42J cell line, as previously described, by exposure to caerulein 164 or H2O2 
165. The AR42J 
cell line is often used as an alternative to primary acinar cells and display essential 
neuroendocrine features of normal acinar cells. Oxidative stress was induced upon caerulein 
exposure as measured by oxidized glutathione (GSSG). Both Rcan1 and Sesn2 expression 
increased rapidly but transiently upon exposure to both caerulein and H2O2. The antioxidant N-
acetylcystein (NAC) dose dependently inhibited the increase of Rcan1 upon caerulein exposure, 
confirming a dependency on oxidative stress for regulation of the gene. NAC alone did not 
induce cell death, indicated by viability measurements using the Acid Phosphatase (APH) 
Assay (as previously described 98) at 1 and 4 hours.  
 
5.1.3 RCAN1 is a potential marker of acute pancreatitis 
Rcan1 protein could be detected by ELISA in the blood of caerulein treated mice compared to 
mock-treated controls. We also found significantly higher levels of RCAN1 protein in the blood 
of AP patients (n = 9, mix of mild, moderate and severe) compared to healthy controls (n = 7). 
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We were, however, not able to demonstrate any difference in RCAN1 levels between mild, 
moderate and severe AP.   
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5.2 Paper II 
 
5.2.1 HMGA2 correlates with shorter overall survival and is a prognostic marker of PDAC 
In pancreatic cancer tissue samples of patients, HMGA2 was found expressed in the nucleus of 
cancer cells, while completely absent in stroma cells, including fibroblasts, immune cells and 
vascular cells. The amount of HMGA2-positive tumor cells however varied between cases and 
both positive and negative tumors were found, consistent with previous data 141-143.  A 
connection was also found between HMGA2 expression and clinic-pathological parameters 
associated with worse prognosis, such as poor tumor differentiation and advanced stage group. 
Further analyses on potential associations between HMGA2 and EMT markers found no 
restriction of HMGA2 to cells with low expression of cytokeratin, as examined by IHC. Nor 
did we find any strong link between HMGA2 expression and investigated EMT-associated 
miRNAs. HMGA2+ cells were however found to be associated with a significantly shorter OS 
and an increased hazard ratio for death in patients with PDAC, identifying HMGA2 as an 
independent prognostic marker.  
 
5.2.2 HMGA2 is differently expressed in human and mouse precursor lesions 
In the KPC mouse model of PDAC, very weak positive staining for Hmga2 was detected in the 
tumor cells already in pancreatic intraepithelial neoplasia (PanIN)-1 lesions, with an increasing 
frequency and intensity in PanIN-2 and PanIN-3 lesions. In the developed murine PDAC, 
heterogeneous staining was observed with positivity primarily in the more poorly differentiated 
part. This is in agreement with HMGA2 expression in established human PDACs, connected 
with poor tumor differentiation (5.2.1). Human PDAC samples contained few PanIN lesions 
and the detected PanIN-1 and PanIN-2 lesions were all negative for HMGA2 (n=18), while no 
PanIN-3 lesions were identified.   
It therefore appears that HMGA2 seems to be differentially expressed within precursor lesions 
in mice and humans. 
 
5.2.3 HMGA2+ tumor cells correlate with PDGFRB+ stroma 
PDGFRB is an important signal transducer of chemotaxis and proliferation of mesenchymal 
cells, which is highly expressed on tumor stroma cells such as cancer-associated fibroblasts 
(CAFs) and pericytes 166, 167. Double IHC staining of PDGFRB and HMGA2 on four different 
human PDAC specimens showed that HMGA2+ tumor cells were more frequent in areas with 
higher abundancy of PDGFRB+ fibroblast. One could however also detect PDGFRB+ stroma 
not linked to high HMGA2 expression in the epithelium and vice versa, although these areas 
were less frequent.  
These observations suggested a role of fibroblasts in the tumor cell HMGA2 induction. 
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5.2.4 PSCs increase HMGA2 expression and tumorigenic properties in PDAC cells 
In order to test whether paracrine interaction is involved in regulation of HMGA2 expression 
and tumorigenic properties of pancreatic cancer cells, Panc1 tumor cells were injected into 
SCID mice, alone or in combination with PSCs. Co-injections resulted in faster growing tumors 
than those derived from Panc1 mono-injections. These faster growing tumors also had higher 
abundance of stroma cells positive for PDGFRB as well as an increased HMGA2 expression in 
tumor cells, both on an mRNA and protein level.  
For further investigations of the impact of PSCs on tumor cell HMGA2 expression, Panc1 cells 
were seeded under anchorage-independent conditions in either control medium, PSC 
conditioned medium or conditioned medium from PSCs pre-stimulated with PDGFB. PSC 
conditioned media increased the ability of Panc1 cells to form tumor cell spheroids under 
anchorage-independent conditions. Conditioned medium derived from PSCs pre-stimulated 
with PDGFB further enhanced this effect. Spheroids grown in either one of the conditioned 
media also showed a slight increase in HMGA2 mRNA expression compared to controls. Using 
a 3D co-culture spheroid model with direct contact between Panc1 and PSCs (characterized and 
validated in paper III), HMGA2 mRNA levels also increased. TGFB1 has previously been 
shown to induce HMGA2 134, which we could confirm in our Panc1 mono-culture spheroids, 
where TGFB1-stimulation induced HMGA2 mRNA expression.   
Together these experiments demonstrate that fibroblasts are able to support HMGA2 expression 
in a manner associated with increased tumorigenic properties. As we did however find most 
PDAC cell lines as well as tissue specimen tumor cells to not express PDGFRs, PDGF ligands 
are unlikely to be part of the CAF secretome inducing HMGA2.  
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 5.3 Paper III 
 
5.3.1. 3D spheroid cultures are healthy and display distinct features  
Electron microscopy as well as morphological analyses showed healthy spheroid cultures, with 
very little apoptosis and necrosis and moderate extracellular matrix, in both Panc1/PSC and 
HPAFII/PSC mono- and co-cultures. 
Panc1 and PSC mono- and co-cultures displayed immature, desmosome-like contact surfaces, 
whereas HPAFII mono-cultures contained large amounts of well-developed desmosomes and 
HPAFII/PSC co-cultures both non-developed and developed desmosomes. The number of 
contact surfaces, immature and mature, increased generally from day 2 to 3 and then stabilized, 
with the exempt of HPAFII/PSC cultures, where desmosome-like structures increased steadily 
over time.  
HPAFII mono-cultures were compact and contained epithelial cells with well-developed 
organelles and good ultrastructure at all time points, as well as fair amounts of microvilli with 
glycocalyx (“sugars”) similar to those seen in the intestines, decreasing with time. HPAFII/PSC 
co-culture cells were round and displayed some microvilli with glycocalix, also here decreasing 
with time. Peripheral cells showed better ultrastructure than centrally located cells. The cell-
cell contacts in the co-cultures were generally good.  
 
5.3.2. PDAC/PSC co-culturing affects cell proliferation and PSC activation  
Immunohistochemical staining with CK19 separated epithelial cells (CK19+) and hPSCs 
(CK19-). Panc1/hPSC co-cultures displayed a mixture of the two cell types throughout the 
cultures, whereas the spatial division between HPAFII cells and hPSCs was clear, as the 
HPAFII cells shaped a wreath around a compact core of stellate cells. CK19 staining of the co-
culture spheroids also allowed to follow the cell type distribution in terms of cell numbers over 
time after initial seeding in a 1:1 ratio. In Panc1/hPSC cultures, the distribution was still equal 
at day 2, after which the hPSCs increased their proportion to around 60%, before stabilizing at 
slightly more than 50%. HPAFII cells on the contrary, made up a somewhat higher proportion 
of the co-cultures than the hPSCs at day 2, and this difference slightly increased over time. 
Staining of another epithelial marker (WT1) confirmed the results of the CK19 staining in the 
Panc1 cultures, but the marker was absent in HPAFII cells. Both Panc1 and hPSCs stained 
positive for vimentin, whereas HPAFII cells were negative. The hPSCs but none of the tumor 
cells were found positive for CD10.  
Double staining with CK19 and the proliferation marker Ki67 revealed that basically all hPSCs 
were proliferating, independent of the presence of tumor cells. The percentage of proliferating 
Panc1 cells increased by co-culture with hPSCs, although the difference to the mono-cultured 
cells decreased over time. Proliferating cell numbers were higher in co-cultured HPAFII cells 
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as well, except on day 5. Real time PCR of spheroid preparations confirmed similar trends 
between mRNA and stainings for CK19, CD10, WT1 and Ki67.  
Markers of activated stellate cells, i.e. α-SMA and the ECM protein fibronectin, were both 
expressed in hPSCs but not in Panc1 mono-cultures, on an mRNA level. Upon co-culture 
expression levels seemingly increased. Collagen type I mRNA expression increased over time 
in Panc1 mono-cultures, while expression remained stable in hPSC mono- and co-cultures. 
None of these genes were expressed in HPAFII mono-cultures. Co-culture of HPAFII and 
hPSCs seemingly increased the expression of fibronectin. TGFB1 mRNA expression suggested 
an increase in co- vs mono-cultured Panc1 cells. It was also found expressed in both HPAFII 
and hPSC mono-cultures, and clearly increased upon co-culture on day 7. 
The protein epithelial marker E-cadherin was strongly expressed in HPAFII cells independent 
of the presence of hPSC, but as expected not at all in hPSCs. Positive staining was present in 
Panc1 mono-cultures and increased over time, however the occurrence was at a much lower 
percentage than in HPAFII cells. Interestingly, E-cadherin was almost non-existent in co-
cultured Panc1 cells. Expression of CDH1, the gene encoding for E-cadherin, was consistent 
with protein data.  
 
5.3.3. Virtual sorting confirms gene expression data from human-human co-cultures 
In paper II, we determined cell type specific mRNA expression in the 3D co-culture spheroids 
by real time PCR upon cell sorting with fluorescence activated cell sorting (FACS) 168. As this 
proved to be unsustainable due to an unreasonably large amount of spheroid cultures being 
required for preparation of a small amount of sample material, and as the prolonged preparation 
time possibly would induce cellular stress and affect gene expression in an unwanted way 169, 
we developed a novel method for determining cell type specific gene expression. This method 
uses normal real time PCR, but with especially designed species specific primers and co-
cultures of human and murine cells. Thanks to the species specificity, intact spheroid co-
cultures can be utilized and no dissociation step is needed. In order to validate the method and 
confirm species-specificity, we ran real time PCR products for each primer pair, from a panel 
of human and mouse tumor cells and stellate cells, on a 2% agarose gel.  
Virtual sorting could confirm an upregulation of α-sma and fibronectin also in mouse PSCs 
(mPSC) co-cultured with Panc1 cells, and of α-sma, collagen type I and Tgfb1 upon co-culture 
with HPAFII cells. Further, the trends of an increase in proliferative (Ki67+) Panc1 cells upon 
co-culture and lower expression of CDH1 in co- vs mono-cultured Panc1 cells, were confirmed 
as well. The method also gave some more insight in gene expressions difficult to interpret in 
the human-human cultures, e.g. an increase of collagen type I and Tgfb1 in PSCs co-cultured 
with Panc1 was suggested. In addition, culture of mouse KPCT tumor cells and hPSCs 
presented the same trend as the other cell combinations when it came to PSC activation, i.e. an 
increased hPSC expression upon co-culture of α-sma, collagen type I, Tgfb1 and fibronectin.         
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5.4 Additional preliminary data  
 
5.4.1 PDGFB does not induce TGFB1 expression in PSCs  
In paper II, we discovered a correlation of PDGFRB-expressing stromal cells and HMGA2+ 
tumor cells. We could also show that PSC conditioned media increased the anchorage-
independent tumor cell spheroid forming ability of Panc1 cells, and that this effect was further 
increased when PSCs were pre-stimulated with PDGFB. As mentioned above in the results of 
paper II, TGFB1 has previously been shown to induce HMGA2 134 and we could confirm an 
upregulation of HMGA2 expression in TGFB1-stimulated Panc1 3D mono-cultures. In paper 
III, we also showed that expression of TGFB1 was induced in co-cultured PSCs. Because of 
this and since PDGFRB-signaling can induce TGFB1 expression 170, we hypothesized that 
PDGFB ligand may induce TGFB1 in the PSCs, ultimately leading to an increase in tumor cell 
HMGA2.    
To test this hypothesis, we treated both regularly 2D cultured PSCs as well as PSC mono-culture 
spheroids with PDGFB, but were unable to detect any alteration of TGFB1 mRNA expression 
(data not shown).  
 
5.4.2 HMGA2 expression is inconsistent in the co-culture spheroid model 
We performed double stainings of CK19 and HMGA2 on the 3D co-culture spheroid models 
using Panc1 or HPAFII PDAC cells and hPSCs, developed and characterized in paper III, as 
well as their mono-culture counterparts. As previously, CK19 stained epithelial tumor cells but 
not PSCs. HMGA2 staining was sparse in Panc1 mono-cultures although increasing over time, 
from day 2 to 7. There was however clearly a higher frequency of HMGA2+ cells in co-cultured 
Panc1 cells (Fig.1A and C). HPAFII mono-cultures contained very few positive cells and co-
cultures showed similar results, except on day 3 where there was a clear spike in HMGA2+ cells 
(Fig.1.B and D). Surprisingly, since using PSCs from the same frozen batch and of similar 
passage numbers, the PSCs in the HPAFII experiment were negative for HMGA2, whereas a 
large percentage of HMGA2+ PSCs were seen in the Panc1 experiment, both in mono- and co-
cultured cells (Fig.1). As to exclude any technical errors, simultaneous staining was performed 
on PSC mono-cultures from both experiments, as well as from two additional replicate 
experiments, one with Panc1 and one with HPAFII cells, mono- and co-cultured with PSCs. 
These stainings showed that only one out of the four experiments (the first Panc1/PSC 
experiment) contained HMGA2+ PSCs (data not shown), in accordance with previous data. All 
samples from the replicate Panc1 experiment, where PSCs were negative for HMGA2, were 
also stained with CK19/HMGA2 double staining and interestingly displayed completely 
different results compared to the Panc1 experiment containing HMGA2+ PSCs. In this case, 
there were surprisingly more HMGA2+ Panc1 cells in the mono-cultures compared to co-
cultures (data not shown).  
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Taken together, this may indicate a strong variation of basal level HMGA2, and a possible 
connection between stromal and tumor cell HMGA2 expression, as HMGA2-positivity in co-
cultured Panc1 cells was increased only in the presence of HMGA2+ PSCs.  
 
 
Figure 1.  Panc1 and PSC (A) and HPAFII and PSC (B) mono- and co-culture spheroids 
stained with CK19/HMGA2. Quantification of HMGA2+ cells in Panc1 (C) and HPAFII (D) 
mono- and co-cultures.  
 
  
Figure 2. A clinical PDAC sample containing areas with strongly HMGA2+ tumor cells in close 
proximity to strongly HMGA2+ stroma, as well as areas completely negative for HMGA2.  
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5.4.3 HMGA2 is differentially expressed throughout clinical PDAC samples 
To try to gain some clarity, we investigated clinical samples that had been stained during 
pathological diagnosis with HMGA2 and CK19, from patients operated for periampullary 
cancer at the Karolinska University Hospital. We found many to be negative for HMGA2, but 
also a few positive. In contrast to the patient cohort investigated in paper II (see section 5.2.1), 
four cases (3 PDACs and one duodenal cancer) displayed HMGA2+ stroma in addition to 
HMGA2+ tumor cells. In all of the four cases both areas with strongly positive tumor cells in 
close proximity to strongly positive stroma, as well as areas completely negative for HMGA2 
were identified (example of a PDAC sample is shown in Fig.2). In two of the PDAC samples 
and the duodenal cancer sample, there also were areas of HMGA2+ tumor cells but a negative 
stroma. Stroma areas positive for HMGA2 without any HMGA2+ tumor cells close by, also 
presented themselves in one of the PDAC samples and in the duodenal cancer sample. The 
PDAC sample containing all of these different areas, tumor+ and stroma+ cells, tumor+ and 
stroma- cells as well as stroma+ and tumor- cells, is shown in Fig.3.  
This data in combination with the protein data from the 3D in vitro co-cultures, together suggest 
a complex relationship between HMGA2-positivity and the cross-talk between tumor cells and 
stroma cells.  
 
 
Figure 3. A clinical PDAC sample containing areas with strongly HMGA2+ tumor cells in close 
proximity to strongly HMGA2+ stroma and areas completely negative for HMGA2 (A), as well 
as with HMGA2+ tumor cells but a negative stroma (B) and stroma areas positive for HMGA2 
without any adjacent HMGA2+ tumor cells (C).   
 
  
41 
 
5.4.4 HMGA2 mRNA expression in the co-culture spheroid model is difficult to interpret 
mRNA levels of HMGA2 in the Panc1/PSC mono- and co-culture spheroids indicated an 
increase of HMGA2 in co-cultures (Fig.4A), consistent with the protein data from the first 
Panc1/hPSC staining experiment. This data was obtained using the same HMGA2 primers as in 
paper II, recognizing different splice variants of the gene. In order to be able to use the virtual 
sorting approach also for investigating tumor cell specific HMGA2 expression in co-cultures, 
human specific primers were designed recognizing either HMGA2 transcript variant 1 
(HMGA2-1) or transcript variant 3 (HMGA2-3), as it due to the similarities between the human 
and murine genome was not possible to compose a universal species specific primer not 
detecting mouse mRNA. Utilizing these species and transcript specific primers on human-
human cultures, indicated an induction of mainly HMGA2-1 in the co-cultures (Fig.4B), 
although HMGA2-3 expression is difficult to interpret due to an interestingly high expression 
in the PSCs (Fig.4C). In HPAFII/PSC cultures, mRNA levels of HMGA2 and seemingly mainly 
HMGA2-1, appeared to be increased in the co-cultures, especially on day 7 when the difference 
was clear (Fig.5A-B). HMGA2-3 was also here more highly expressed in the hPSCs than the 
HMGA2-1 transcript (Fig.5C), however not at the levels seen in the Panc1/PSC experiments.  
 
 
 
Figure 4. HMGA2 mRNA expression for Panc1 and hPSC mono- and co-cultures normalized 
to Panc1 mono-culture spheroids from day 3. Total HMGA2 (A), HMGA2 transcript variant 1 
(HMGA2-1) (B) and HMGA2 transcript variant 3 (HMGA2-3) (C) expression, from indicated 
time points (n=3-5).   
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Figure 5. HMGA2 mRNA expression for HPAFII and hPSC mono- and co-cultures normalized 
to HPAFII mono-culture spheroids from day 3. Total HMGA2 (A), HMGA2 transcript variant 
1 (HMGA2-1) (B) and HMGA2 transcript variant 3 (HMGA2-3) (C) expression, from indicated 
time points (n=3-5).   
 
Figure 6. HMGA2 mRNA expression for Panc1 and HPAFII mono- and co-cultures with 
mPSCs, normalized to either Panc1 (A-B) or HPAFII (C-D) mono-culture spheroids from day 
3. HMGA2 transcript variant 1 (HMGA2-1) (A, C) and HMGA2 transcript variant 3 (HMGA2-
3) (B, D) expression, from indicated time points in mono- and co-cultured tumor cells (n=3).  
 
Using the virtual sorting approach on Panc1 and HPAFII cells cultured with mPSCs, could not 
confirm the data from the human-human cultures. When co-cultured with mPSCs, HMGA2-3 
was induced in the Panc1 cells and not HMGA2-1 as indicated by the human-human cell data 
(Fig.6A-B). In the HPAFII cells, HMGA2-1 was induced only on day 3 instead of also at day 7 
as when co-cultured with the hPSCs (Fig.6C). In addition, HMGA2-3 was clearly induced in 
HPAFII cells co-cultured with mPSCs (although not significantly) (Fig.6.D), something that 
was not to be expected based on the co-culture together with the hPSCs. 
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5.4.5 TGFB1 induces HMGA2 but the mechanism behind is unclear 
As we in paper II could show that TGFB1 induced mRNA expression of HMGA2 in the Panc1 
mono-culture spheroids, we decided to further investigate the connection between TGFB1 and 
HMGA2. By preparing paraffin sections of mono-cultured Panc1 spheroids stimulated with 
TGFB1, we could confirm that HMGA2 was upregulated in the Panc1 cells also on a protein 
level (Fig.7.A-B). Not surprisingly by adding a growth factor to serum starved cells, there also 
was an increased number of proliferative (Ki67+) cells (Fig.7.C-D) as well as a downregulation 
of apoptotic (M30+) cells (Fig.7.E-F), upon TGFB1-stimulation.  
 
Figure 7. CK19/HMGA2 (A), CK19/Ki67 (C) and M30 (D) staining in Panc1 control and 
TGFB1-stimulated mono-cultures from days 5 and 7. Quantification of the stainings are seen 
in (B, D, and F).  
 
In a cell panel of normal but immortalized human pancreatic ductal epithelial cells (HPDE), 
PSCs and a number of PDAC cell lines, TGFB1 and HMGA2 mRNA levels were shown to be 
in parallel for almost all cell lines in both 2D and 3D mono-cultures (Fig.8A-D). Internal 
controls with Panc1, Panc1-Mock (Panc1-M) and Panc1 TGFB-overexpressing (Panc1-T) cells, 
could further confirm this. Out of the three PDAC cell lines that did not have a clear 
synchronization between levels of TGFB1 and HMGA2, one was Smad4-negative and one 
Smad4 mutated. All other cell lines in the panel were wild type for Smad4. Interestingly, PSCs 
did not display higher levels of HMGA2 with higher levels of TGFB1 in the 3D cultures. 
TGFB1-stimulation of mono-cultured HPAFII and PaCa44 cells, with low endogenous levels 
of TGFB1, did not induce HMGA2 expression as seen in the Panc1 cells (data not shown).    
In order to investigate the effects of TGFB1 on co-culture induced expression of HMGA2, we 
treated mono- and co-cultures with TGFB-inhibitors. This however gave inconclusive results, 
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due to inconsistency of both the inhibitor effects and the co-culture induced expression itself 
(data not shown). Preliminary data on mRNA expression of HMGA2 and TGFB1 in tumor cells, 
as well as TGFB1 in PSCs, from 3D mono- and co-cultures, was in line with some of the 
previous data and indicated that HMGA2 levels in the tumor cells mimicked TGFB1 levels in 
the same, but were independent of highly increased TGFB1 mRNA expression in the PSCs 
(data not shown). Interestingly, expression of HMGA2-1 and -3 transcripts in the 2D-culture 
cell panel showed that HMGA2-1 but not -3, was synchronized with TGFB1 expression (Fig.8E-
F).
 
 
Figure 8. HMGA2 (total, transcript variant -1 and -3, as indicated) and TGFB1 mRNA 
expression normalized to human pancreatic ductal epithelial (HPDE) cell expression, in a cell 
line panel of  HPDE cells, human pancreatic stellate cells (hPSC), Panc1 Mock control (Panc1-
M) and TGFB1-overexpressing (Panc1-T) cells, and a number of pancreatic cancer cell lines 
(Panc1, HPAFII, PaCa44, CFPAC-I and Capan-I),  in 2D (A-B and E-F) and 3D (C-D) cultures. 
Smad4 status of the cells is indicated below (C-D).   
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6. DISCUSSION 
 
6.1 Paper I 
6.1.1. The caerulein model 
The validity of caerulein induced AP has been questioned, due to the potential lack of 
physiological relevance, as the existence of CCK receptors on human acinar cells still remain 
to be proven. Rodent pancreatic acini, in contrast to human acini, respond to physiological 
concentrations of CCK in vitro. CCK-A receptors are present on rodent but not on human acinar 
cells, and it is generally accepted that exocrine pancreatic stimulation in humans is almost 
exclusively mediated through the cholinergic stimulation, where as in rodents direct CCK-A 
stimulation plays a role in addition to cholinergic stimulation 52, 171. Caerulein however, induces 
pancreatitis by increasing levels of intracellular calcium and thereby activating calcium 
dependent CN-NFAT signaling 30. As does bile acid 34, 172, one of the two major clinical causes 
of AP 15. This strongly supports the use of the caerulein induction model for studying the 
downstream effects of CN activation, independent of the true mechanism behind the initiation 
of the intracellular calcium induction. 
 
6.1.2 AR42J cells as a substitute for primary acinar cells 
AR42J cells are often referred to in the literature as rat acinar cells, although they are in fact 
derived from a transplantable tumor of rat exocrine pancreas. Caution should therefore be taken 
when using these cells for studying normal acinar cell function. The cells do however retain 
many characteristics of normal acinar cells. They are able to synthesize, store and secrete 
digestive enzymes (Jessop & Hay 1980) 173, and elicit normal receptor expression and signal 
transduction mechanisms 174. Primary human acinar cells, due to their nature as specialized 
secretory cells, are still difficult to culture and they have not been possible to maintain long-
term 175. When acinar cells are taken out of their natural environment they lose their cellular 
identity and transdifferentiate into ductal cells. Transfection of these cells also has been 
challenging and no long-term cultures of normal acinar cells has yet been reported 176, although 
now both murine 158, 177 and human 178 primary acinar cells have been cultured for more than 1 
week. Until primary acinar cell culture becomes more reliable, there still is a good reason for 
the use of the AR42J cell line, of course after validation of use and for appropriate scientific 
questions.  
 
6.1.3 RCAN1 as a marker of AP and inflammation 
As RCAN1 is inhibiting its own induction through binding and blocking calcineurin, high initial 
increase of RCAN1 should in theory inhibit further production. This is in line with our data 
showing an early peak of Rcan1 mRNA expression, with a declination at later time points 179. 
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As illustrated in Suppl. Fig.2 in paper I, CCK increases intracellular Ca2+ levels, thus activating 
the CN-NFAT axis and inducing RCAN1. CN activity and the CN-NFAT axis is then blocked, 
once there is enough RCAN1 protein. This leads to a reduction of RCAN1 mRNA and 
degradation of RCAN1 protein, thus causing oscillation.  
Rcan1 protein in murine blood was also detected early upon onset of experimental AP, 
indicating the potential of RCAN1 as an early marker of AP, a quality desirable for clinical use. 
One potential specific use could, as mentioned in the discussion of paper I, be in the case of 
Endoscopic Retrograde Cholangiopancreatography (ERCP). Post-ERCP-pancreatitis, or PEP, 
develop in up to 15% of patients 180 and ERCP has been shown to cause acinar cell inflammation 
and injury through induction of CN signaling 181. Preventative treatment of PEP with CN-
inhibitors 180 has potential, and RCAN1 as a marker of the success of such treatment could be 
a good complement.  
A fast decline of RCAN1 protein due to aforementioned oscillation, could on the contrary be 
potentially problematic as it would limit the window of detection. A continuous stimuli in the 
clinical situation would however likely override the auto-regulation and maintain an induction 
of RCAN1. Protein levels may also persevere for extended time independent of inhibition of 
further mRNA production, something that requires further investigations.  
In paper I, we demonstrated that RCAN1 was regulated by oxidative stress. RCAN1 mRNA 
was induced by caerulein and H2O2 and this induction was inhibited by the antioxidant N-
acetylcystein (NAC) (Fig.2 in paper I). A major limitation of RCAN1 as a diagnostic marker 
would be the plausible lack of specificity, as an indirect marker of oxidative stress merely is a 
marker of inflammation and not a specific marker for AP. As ROS is correlated with AP 
severity, it could however prove to be of clinical value as a prognostic marker. As mentioned 
in the discussion of paper I, measuring ROS directly or indirectly through metabolites still 
remains challenging and it has therefore not been implemented into a clinical setting 53. In our 
studies, we were however not able to stratify the RCAN1 levels in patients with mild, moderate 
and severe AP. In the discussion of the paper, we mention that one possibility is that this could 
be due to a short-lived transient induction of RCAN1 protein, which would coincide with 
oscillation of RCAN1 protein due to the CN-NFAT – RCAN1 loop described above, and our 
mRNA data. The above reasoning with continuous stimuli in the clinical setting likely 
overriding this auto-regulation, would however on the contrary argue for the continuous 
potential of RCAN1 as a prognostic marker, once better tools for RCAN1 detection will be 
available.   
Another possible application for RCAN1 is as an alternative endpoint in anti-oxidant trials. As 
there are no evidence of RCAN1 enhancing pancreatic inflammation, it is not itself a feasible 
therapeutic target at the moment. On the contrary, treatment with RCAN1 or rather other 
synthetic inhibitors of calcineurin, would be the more prominent strategy for inhibiting the 
inflammatory response. As mentioned, CN-inhibitors already have been successfully tested for 
prevention of PEP. The potential of RCAN1 as an end-point for anti-oxidant trials however 
extends way beyond the use of CN-inhibitors in ERCP patients. Antioxidants have been 
thoroughly tested as a treatment for AP, mainly pointing at no benefit when used as 
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monotherapy 179, but the potential of combination therapies including antioxidants still needs 
to be further explored.  
As suggested in paper I, RCAN1 may also prove useful as a marker of AP patients who might 
benefit from a specific therapy, as opposite results of CN-inhibitors have been demonstrated 
using different AP models, indicating that different treatment approaches may be necessary 
depending on the etiology of the disease.  In addition, as a marker of oxidative stress and thereby 
inflammation, there also is a possibility that RCAN1 may prove useful beyond the scope of AP.  
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6.2 Paper II 
This study demonstrated a negative connection between PDAC survival and HMGA2 IHC 
expression in tumor cells, and linked PDGFRB+ fibroblasts to tumor cell HMGA2 expression. 
Our findings strongly advocate a contribution of paracrine stroma-epithelial signaling to 
HMGA2 expression, encouraging further studies investigating the cross-talk mechanisms 
behind HMGA2 induction. As some studies were already carried out in this direction, presented 
in section 5.4, this is further discussed along with the discussion of this additional data, in 
section 6.4.   
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6.3 Paper III 
 
6.3.1 Advantages and limitations of the 3D co-culture spheroid model 
Our novel established 3D PDAC and PSC co-culture spheroid model has been very well 
characterized, as has each of the separate cell lines used 182. Important advantages of this type 
of co-culturing model is that genes of interest involved in PDAC-PSC crosstalk can be 
overexpressed and knocked out. Thus, co-cultures with a specific genetic alteration can be 
compared to controls, eliminating difficulties in comparing co-cultures to mono-culture 
counterparts, where cell numbers as well as physical location of a cell type within the spheroid 
may vary and affect the outcome. Well characterized fluorescent cell lines may also be used as 
a substitute for the parental lines, expanding further the capabilities of the model. With 
fluorescent cell lines more scientific questions may be addressed using intact spheroid cultures 
in e.g. confocal microscopy. When suitable, cells can also be dissociated and used for flow 
cytometry and fluorescent activated cell sorting (FACS). Preparations of fluorescent cell lines 
and their characterization (Panc1-mCherry, HPAFII-mCherry, HPDE-mCherry, hPSC-eGFP 
and mPSC-eGFP), is currently ongoing in the laboratory (data not shown).    
Using any model of immortalized cell lines as in our model may of course limit and or change 
certain characteristics and cell behaviors in comparison to primary cells, something that needs 
to be taken into consideration. Primary cells however sometimes do not survive at all ex vivo 
and if they do they may not be grown for the same amount of time and cannot be manipulated 
as described above. In order to be able to address various scientific questions, a variety of 
experimental models is needed and the appropriate model should be chosen depending on the 
question asked.   
The lack of a rich ECM might be considered a disadvantage of the model, as the desmoplastic, 
fibrotic stroma has become the general picture of a PDAC, and for some studies that is certainly 
true. It has to be remembered however, that tumors are heterogenic and that the common notion 
of stroma rich PDACs composed to a large extent of ECM is not the whole truth. There are 
great variations in the amount of stroma in between different PDACs. Importantly, there are 
also different regions of tumors that are more and less composed of ECM 183, something that 
might depend on local variations in the microenvironment. As we have learned, there are 
various types of CAFs and PSCs with different markers and behaviors 89, 184. With such a 
complex reality, we cannot limit ourselves to study only a certain type of PDAC. 
As compared to traditional 2D cell culture, 3D cultures offer an environment more closely 
resembling the reality, although for the same reasons cause more technical difficulties and 
challenges than 2D culturing 185. They e.g. give rise to different populations of cells exposed to 
various amounts of nutrients, oxygen and experimental treatments etc., depending on their 
localization within the spheroid. This is desirable but often makes it more difficult to interpret 
experimental outcomes. Additional issues are introduced with 3D co-culturing, such as which 
appropriate controls may be used. Accurately comparing co-culture spheroids to the mono-
culture equivalents is not straight forward, as the cell numbers of any given cell type, spheroid 
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size etc. may differ. Keeping one parameter constant will alter another, and we need to find new 
ways of designing experiments in a meaningful way as to be able to answer our question at 
hand and provide easily interpretable results.  
As an example, imagine investigating migratory properties of the tumor cells in our co-culture 
model compared to the mono-culture counterpart. If one keeps tumor cell numbers in the two 
cultures the same, the spheroid sizes will differ due to the addition of another cell type to the 
co-cultures. In a model such as our Panc1/PSC model where the tumor cells and the PSCs are 
mixed throughout the spheroid, the average distance for the tumor cells within the co-cultures 
to migrate before reaching the surface, would be longer. In order to have the same number of 
cells with the same distance to migrate, cells would need to first be dissociated and sorted. This 
would instead however, as previously discussed in paper III, increase preparation time and 
induce cellular stress, possibly affecting the outcome. In order to not dissociate the spheroids, 
a 3D sprouting assay, where intact spheroids are placed in a gel or ECM allowing cells to 
migrate out from the spheroid and into the matrix, is a valid option. The difference in average 
distance for cells to migrate would however still remain, and interpretation of the results would 
still be difficult. A better way may therefore be to first identify a potential genetic target that is 
likely involved in migration, manipulate the tumor cells to overexpress the gene of interest or 
knock it out, and then compare these co-cultured tumor cells to co-cultured appropriate tumor 
control cells.  
 
6.3.2 Advantages and limitations of the virtual sorting method 
The main advantage of the virtual sorting method, and the reason for us developing it, is the 
elimination of the need to dissociate and sort the cells composing the spheroids. As previously 
discussed in paper III, this does not only save valuable time and resources, but more importantly 
eradicates added cellular stress.  
A major disadvantage is that cells of different species needs to be used. If initial studies have 
been performed in human cells, one cell line has to be exchanged for e.g. a murine cell line in 
order to use the method. This may in itself alter the experimental response as different cell lines 
of the same cell type can greatly differ. It is therefore crucial to first confirm that the parameters 
important to the specific scientific question are similar in the two cell lines.  
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6.4 Additional preliminary data 
 
6.4.1 PDGFRB – HMGA2 link 
Obtained data show that PDGFRB is not involved in induction of HMGA2 through TGFB1 
induction in the PSCs. PDGFRB-signaling might induce other factors involved in the induction 
of HMGA2, or PDGFRB may be a marker of a CAF-subpopulation exhibiting a certain 
secretome inducing tumoral HMGA2 expression.  
 
6.4.2 HMGA2 expression 
HMGA2 expression was found in PDAC to be associated with loss of tumoral E-cadherin 
expression 131, much like our observations in the Panc1/PSC co-culture spheroids. In paper II, 
we found that HMGA2 was correlated to overall survival in PDAC, but could be detected in 
tumor cells independent of their epithelial cell differentiation status. The stroma in the clinical 
samples in paper II was negative for HMGA2, but we did identify a few cases with HMGA2+ 
stroma (additional preliminary data, section 5.4.3), both adjacent to HMGA2+ tumor cells as 
well as isolated. Of note, the scoring of HMGA2 in the patient cohort from paper II was done 
without the additional CK19-staining used for the clinical samples and the spheroids in the 
additional data, and the staining protocols somewhat differ in terms of antibody incubation time, 
potentially causing discrepancy. 
Preliminary results from the spheroid model indicated a potential connection between HMGA2+ 
stroma and HMGA2+ tumor cells (5.4.2), and more strongly positive tumor cells were found 
adjacent to strongly positive stroma cells in the desmoplastic stroma positive clinical samples 
(5.4.3). Interestingly, overexpression of stromal Hmga2 in prostate cells, lead to the formation 
of multifocal prostatic precancerous lesions in neighboring epithelium, in a paracrine Wnt-
dependent manner 186.  
Our inconsistent results of HMGA2 expression in both tumor cells and PSCs in the 3D co-
culture spheroid model might reflect a complex reality, but makes our results difficult to 
interpret at the moment and does not explain the observed differences using the same model 
with no apparent experimental differences. It however encourages further studies and suggests 
our Panc1/PSC co-culture model as an appropriate model for continued investigations.  
 
6.4.3 HMGA2 transcripts 
As explained above, HMGA2-1 was increased at an mRNA level in the HPAFII cells and also 
in the Panc1 co- vs mono-cultured cells seemingly mainly HMGA2-1 transcript expression was 
induced. In the Panc1/hPSC co-cultures, HMGA2 protein was induced in co- vs mono-cultured 
Panc1 cells whereas no protein induction was seen in the HPAFII co-cultured cells. HMGA2-3 
was highly expressed in the hPSCs (also mono-cultures) in the Panc1/hPSC experiment but not 
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as clearly in the HPAFII/hPSC experiment. HMGA2 protein was found expressed in the hPSCs 
only in the Panc1/hPSC experiment. HMGA2 protein was also induced by TGFB1 stimulation 
in the mono-cultured Panc1 spheroids, and according to our preliminary data HMGA2-1 but not 
HMGA2-3 expression is influenced by TGFB1 levels in the tumor cells themselves.  
The HMGA2 antibody used recognizes the N terminus of the protein, which is conserved in all 
the transcript variants. Taken together, the HMGA2 mRNA transcript data creates more 
questions than answers. The inductions seen in mRNA expression do not always translate into 
an increase of HMGA2 protein. The mRNA data is difficult to interpret with both the tumor 
cells and hPSCs expressing HMGA2. The mPSC cell line used may not adequately reflect 
similar HMGA2 expression as the hPSCs, and the virtual sorting experiments do not clarify the 
situation in this case. Another mPSC cell line more similar to the hPSCs in terms of HMGA2 
expression may be considered for further experiments, but the relevance of various transcript 
variant expression may be limited and focus will likely be better used elsewhere.  
 
6.4.4 TGFB1 induced induction of HMGA2 
As mentioned, hPSCs did not display higher levels of HMGA2 with higher levels of TGFB1 in 
3D mono-cultures. Preliminary data also indicated that induction of HMGA2 expression in the 
Panc1/PSC co-cultures followed TGFB1 expression in the Panc1 cells and not in the PSCs. 
Taken together, this indicates that expression of HMGA2 in the stroma seen in the clinical 
samples and in the PSCs in the 3D mono- and co-cultures, are induced by other means than 
PSC-produced TGFB1. The PSCs may have low levels of or not at all express TGFBRs, 
therefore not upregulating HMGA2 themselves. There also is a possibility that the receptors are 
there but that the PSCs are not able to induce HMGA2 through autocrine signaling. There might 
not be any translation of the TGFB1 mRNA in to protein in the stellate cells, or the protein may 
be instantly degraded in these cells. It is however possible that the presence of PSCs might 
induce TGFB1 expression in the tumor cells themselves, ultimately leading to an increase in 
HMGA2.  
The fact that TGFB1 stimulation did not induce HMGA2 expression in the HPAFII and PaCa44 
cells might also be due to a lack of TGFBRs in these cell lines. HMGA2 is not expressed in all 
PDACs, although PaCa44 cells do express rather high levels of HMGA2 mRNA in 2D culture. 
It is however plausible to believe that HMGA2 is induced by multiple pathways and not only 
by TGFB1.  
Clearly, the relationship between HMGA2-positivity in PDAC cells and PSCs, as well as the 
induction of HMGA2, is complex. Our preliminary data opens up for many questions and a 
deeper investigation is needed to elucidate the mechanism behind.    
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7. CONCLUSIONS 
 
Paper I: 
 RCAN1 is regulated by oxidative stress and is an early marker of the same.  
 RCAN1 has the potential to be used as a surrogate endpoint in anti-oxidant therapy 
trials, as a marker of AP patients who might benefit from a specific therapy, a diagnostic 
marker for ERCP-induced pancreatitis and possibly as a prognostic marker of AP 
severity.  
 As a marker of oxidative stress and thereby inflammation, RCAN1 may also prove 
useful beyond the scope of AP. 
 
Paper II: 
 HMGA2-positivity is a strong prognostic factor for shorter overall survival in PDAC. 
 HMGA2 IHC can identify patients with a worse prognosis. 
 Continued efforts are warranted to define novel fibroblast subsets for further exploration 
of their regulation, function and clinical importance. 
 
Paper III:  
 Our novel 3D co-culture spheroid model of PDAC cells and PSCs, can be used to study 
tumor cell – PSC cross-talk.  
 Virtual sorting may be used to determine cell type specific gene expression in direct 
cellular co-cultures of mixed species, without previous cell separation.  
 
Additional preliminary data: 
 PSC PDGFRB-signaling is not inducing TGFB in the PSCs and may not be involved in 
HMGA2 induction, but rather a marker of a CAF-subpopulation inducing tumor 
HMGA2 expression. 
 HMGA2 expression in tumor cells and tumor stroma and the relationship in between is 
complex and requires further investigations. 
 Our Panc1/PSC co-culture model is likely an appropriate model for studying tumor 
HMGA2 induction. 
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8. FUTURE PERSPECTIVES 
 
In paper I, we found RCAN1 to be an early marker of AP and suggested its use as a marker of 
post-ERCP-pancreatitis (PEP). A study further investigating this potential is already planned 
for. The ethical application has already been approved by Regionala etikprövningsnämnden in 
Stockholm and patient samples are currently being collected.  
Once better tools for RCAN1 detection are available and/or the oscillation of RCAN1 has been 
better understood, a bigger study on correlation between RCAN1 expression and AP severity 
would be interesting to see. It would also be exciting to see the use of RCAN1 evaluated in 
other inflammatory diseases than AP, as well as one of the endpoints in antioxidant therapeutic 
studies, for AP as well as other diseases.  
Regarding our findings in paper II, I foresee that HMGA2 IHC in the future will be part of the 
standard clinical evaluations of PDAC patients as a prognostic marker. More mechanistic 
studies are however needed to understand how HMGA2 is contributing to lower survival and 
how it is induced in the tumor cells. Of special interest to me would be to explore the 
relationship between HMGA2 in the stroma and the tumor cells and how the stroma is 
contributing to increased tumor cell expression. Involvement of e.g. the Wnt pathway has as 
mentioned been suggested in other cancers and it would be interesting to explore its role in 
pancreatic cancer, alongside further clarification of the involvement of TGFB1. Our 3D co-
culture human-human cell spheroid model characterized in paper III is ready to be used for 
further mechanistic studies, and as suggested from our preliminary data could be a good model 
for mechanistic studies of HMGA2.  
PDGFRB stainings of Panc1/PSC mono- and co-culture spheroids are ongoing, in order to 
explore if there is any correlation between PDGFRB+ stroma and HMGA2+ tumor cells in this 
model, as seen in the clinical samples in paper II. It would also be interesting to further study 
PDGFRB+ stroma cells and explore if anything in this population of CAFs can contribute to 
HMGA2 induction in the cancer cells. Isolating PDGFRB+ CAFs and studying their secretome 
might identify new potential pathways in the stroma and tumor cell communication, important 
for HMGA2 induction and the correlated lower survival of PDAC patients.  
The virtual sorting method developed in paper III has the potential to be implemented in many 
studies far beyond the scope of pancreatic diseases. I believe that this model will find its place 
as an additional scientific tool where applicable. For our HMGA2 mechanistic studies I 
however believe that we need to focus elsewhere due to the lack of universal species specific 
primers.  
Generally, I expect to see a continued increase of studies in regard to cancer and the tumor 
microenvironment. I anticipate an even more complex image to emerge, revealing many more 
different subtypes of CAFs and PSCs than known today, influencing tumor progression in 
different ways depending on the context. Revelations of intricate communication involving also 
additional cell types, such as TAMs and other immune cells, endothelial cells etc. is to be 
expected, as we will learn how to understand their conversations.   
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